Nipro Pharma Corporation

What Nipro Pharma Corporation does

Nipro Pharma Corporation (ニプロファーマ株式会社) is a Japanese pharmaceutical contract development and manufacturing organization (CDMO) and a wholly-owned subsidiary of Nipro Corporation (Tokyo Stock Exchange: 8086). Founded in 1948 in Osaka and headquartered in Settsu City, Osaka, the company operates 12 manufacturing sites — 11 domestic plants across Akita, Mie, Fukushima, Shiga, Osaka, and Saitama prefectures, plus one overseas site in Hai Phong, Vietnam. Its stated capital is 8,669 million yen, and it employs approximately 4,177 people as of March 2026.

The company manufactures pharmaceutical products on a B2B contract basis across all three major dosage forms: injectables (ampoules, vials, pre-filled syringes, dual-chamber syringes, lyophilized vials, double-bag kits), oral products (tablets, capsules, granules, orally disintegrating tablets, high-potency formulations), and external preparations (transdermal patches, tapes, ointments). Core technical differentiators include proprietary kit formulations (PFS, PLW double-bag, D-PFS dual-chamber syringe), transdermal drug delivery systems, lyophilization for biologics, and dedicated high-containment isolated facilities for high-potency drugs including anticancer agents, antibiotics, and steroids. Manufacturing operations hold FDA certification (Odate aseptic, Kagamiishi solid dose), EU GMP, Japanese GMP, and PIC/S WHO-GMP compliance, with the Vietnam site PIC/S certified.

Nipro Pharma generates revenue through per-batch contract manufacturing fees and long-term supply agreements with Japanese and international pharmaceutical companies, supported by sales through Nipro Corporation's pharmaceutical division. Customer segments include ethical and generic pharmaceutical manufacturers seeking injectable, oral, and external formulation capacity, as well as clients needing high-potency, biologic, or clinical trial material production. Recent customers include AstraZeneca for COVID-19 vaccine contract manufacturing. Distribution is indirect — finished products are delivered to client pharmaceutical companies, which then handle downstream distribution through pharmacy, hospital, and wholesaler networks, supported by a GDP-compliant logistics partnership with Suzuyo Corporation.

Name

Nipro Pharma Corporation

Legal name

ニプロファーマ株式会社

Website

https://np.nipro-pharma.co.jp

Company type

Private

Founded year

1948

Operating status

Operating

Headcount range

11–50 employees

Short description

Nipro Pharma Corporation is a Japanese pharmaceutical CDMO and wholly-owned subsidiary of Nipro Corporation that contract-manufactures injectables, oral products, and external preparations across 12 sites in Japan and Vietnam, serving domestic and global pharmaceutical companies under FDA, EU, and PIC/S GMP certifications.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Small-Molecule API & Intermediates CDMO (HLAGABAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical contract manufacturing
• Sterile injectable manufacturing
• Oral solid dosage manufacturing
• Transdermal drug delivery
• CDMO services

Headquarters

HQ city

Settsu City (Osaka)

HQ country

Japan

HQ region

Asia

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Pharmaceutical Manufacturing: Nipro Pharma operates as a CDMO earning revenue by manufacturing pharmaceutical products (injectables, oral, external) on behalf of pharmaceutical company clients. Revenue is derived from long-term manufacturing contracts and per-batch production fees. Services span from generic drug manufacturing to high-value-added formulations including kit products, biologics, and clinical trial materials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Nipro Pharma Corporation is a pharmaceutical contract manufacturer (CDMO) that produces injectable, oral, and external dosage forms on behalf of pharmaceutical company clients. It runs 12 manufacturing sites (11 in Japan and 1 in Vietnam) with multi-regional GMP compliance (Japan/US/EU/PIC/S), and is differentiated by proprietary kit formulations (PLW® double bags, D-PFS®, PFS®), high-containment isolated manufacturing for high-potency drugs, and small-quantity pharmaceutical packaging services.

Product overview

Nipro Pharma Corporation is a comprehensive pharmaceutical contract manufacturing organization (CMO/CDMO) offering end-to-end services across all major dosage forms: injectables, oral products, and external preparations. The portfolio includes specialized kit formulations (PLW, D-PFS, PFS) that combine drugs with delivery devices, high-potency active pharmaceutical ingredients manufactured in isolated facilities, and advanced DDS technologies for controlled release and patient compliance. Manufacturing is supported by quality testing services at dedicated analysis centers, while the Hida Factory subsidiary provides small-quantity pharmaceutical packaging including PTP, bottles, and clinical trial supplies. Global operations span Japan and Vietnam with multi-GMP compliance (Japan/US/EU/PIC/S) serving pharmaceutical companies worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• PLW (Double Bags): Liquid-powder double bag kit system for injectable pharmaceuticals
• PFS (Pre-filled Syringes)
• D-PFS (Double Chamber Pre-filled Syringes)
• Genepack (ジェネパック)

Quantifiable outcome

• Reduction of foreign object contamination, bacterial contamination, and needle-stick injury risks through kit formulations (PFS®, double bags)
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered notable, core and minor.

• AstraZenecanotableStrategic or Co-development Partner · 26 May 2021AstraZeneca contracted Nipro Pharma to manufacture the formulation process for their COVID-19 vaccine 'Vaxzevria™ Intramuscular Injection' (バキスゼブリア筋注) for the Japanese market.
• Suzuyo CorporationcoreStrategic or Co-development Partner · 1 September 2018Logistics partnership with Suzuyo Corporation for GDP-compliant pharmaceutical logistics and integrated supply chain management at Ise Plant's dedicated logistics warehouse (operational from September 2018).
• MecoPharma (Vietnamese pharmaceutical company)minorStrategic or Co-development Partner · 1 November 2016Capital partnership established with Vietnamese pharmaceutical company MecoPharma in November 2016 as part of Nipro Pharma's Vietnam market entry strategy.

Scale indicators6 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• AGC Pharma (AGC Inc.): Pharmaceutical CDMO division of AGC Inc. offering injectable, oral, and biologics contract manufacturing globally. Comparable as a Japanese-headquartered CDMO with multi-modality offerings and international footprint.
• Bushu Pharmaceuticals: Japan-based contract manufacturer of injectable and oral pharmaceutical products. Directly comparable as a domestic Japanese CDMO serving pharmaceutical companies with similar filled-vial, ampoule, and tablet capabilities.
• CMIC Group: Japanese CRO/CDMO providing contract manufacturing, clinical development, and analytical services. Comparable as a Japan-anchored CDMO offering across multiple dosage forms with regulatory and analytical infrastructure.

Others

• Suzuyo Corporation: Japanese logistics and pharmaceutical distribution partner. Listed here because Suzuyo is Nipro Pharma's GDP-compliant logistics partner at Ise Plant, providing a tangible ecosystem linkage between pharmaceutical manufacturing and regulated distribution.

Broad incumbents

• Catalent (Novo Holdings): Global CDMO with strong oral dosage, injectable, and biologic capabilities. Comparable as a multi-modality CDMO serving top-tier pharma customers with proprietary drug delivery and softgel technology platforms.
• Siegfried Holding: Swiss-headquartered global CDMO with API and finished drug product manufacturing. Comparable as a full-service CDMO with multi-GMP facilities and broad geographic reach serving global pharma clients.
• Samsung Biologics: Korean global CDMO focused on biologics contract manufacturing. Comparable as a large-scale, internationally GMP-compliant CDMO targeting biologic and high-potency injectable contracts.
• Lonza Group: Global CDMO leader in biologics, small molecules, and cell/gene therapy. Comparable as a large-scale, multi-modality CDMO with FDA-approved facilities and PIC/S compliance serving global pharma customers.

Regional players

• Nichi-Iko Pharmaceutical: Japan's largest generic drug manufacturer with internal manufacturing of injectables, oral solids, and external preparations. Comparable as a Japanese pharma manufacturer with significant captive CDMO capacity and DMF filings.
• Towa Pharmaceutical: Japanese generic pharmaceutical manufacturer with vertically integrated contract manufacturing capabilities. Comparable as a domestic Japanese manufacturer offering oral and injectable production at scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nipro-pharma-corporation

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nipro Pharma Corporation